New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
07:18 EDTBCRXBioCryst upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo upgraded BioCryst to Outperform saying the stock is not pricing in the likelihood of success for BCX-4161 in Hereditary Angioedema. Wells raised its price target range for shares to $17-$19 from $8-$9.
News For BCRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
13:24 EDTBCRXLiberia, U.S. begin ZMapp ebola trial
In partnership with the Liberian government, the National Institute of Allergy and Infectious Diseases launched a clinical trial to obtain safety and efficacy data on the investigational drug ZMapp as a treatment for Ebola virus disease. The study may be expanded to test ZMapp against other treatments which may also include the following: Tekmira siRNA from Tekmira Pharmaceuticals (TKMR), Favipiravir from Toyama Chemical, BCX4430 from BioCryst (BCRX), and AVI-7537 from Sarepta (SRPT). The trial is expected to conclude in December 2016.
February 18, 2015
06:58 EDTBCRXBioCryst sees FY15 operating expenses $75M-$95M
Subscribe for More Information
06:57 EDTBCRXBioCryst reports Q4 EPS (16c), consensus (21c)
Reports Q4 revenue $5.4M, consensus $3.64M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use